Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

van den Bent, Martin J; Baumert, Brigitta; Erridge, Sara C; et al; Stupp, Roger

doi:10.1016/S0140-6736(17)31442-3

UZH-Logo

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

van den Bent, Martin J; Baumert, Brigitta; Erridge, Sara C; et al; Stupp, Roger (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, 390(10103):1645-1653.

Find similar titles

Citations

Dimensions.ai Metrics

230 citations in Web of Science®
252 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

362 downloads since deposited on 27 Oct 2017
31 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:	Journal Article, refereed, original work
Communities & Collections:	04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:	610 Medicine & health
Scopus Subject Areas:	Health Sciences > General Medicine
Language:	English
Date:	8 August 2017
Deposited On:	27 Oct 2017 07:01
Last Modified:	22 Nov 2023 08:20
Publisher:	Elsevier
ISSN:	0140-6736
OA Status:	Green
Free access at:	PubMed ID. An embargo period may apply.
Publisher DOI:	https://doi.org/10.1016/S0140-6736(17)31442-3
PubMed ID:	28801186